AGC acquires a leading German biopharma CMO

Furthering its ambitions in the medical sector, Japanese glass manufacturer AGC Asahi Glass says it has acquired all of the shares of Biomeva GmbH from Germany’s Biomeva Holding GmbH. Financial terms of the transaction were not disclosed.

Biomeva is one of the leading biopharmaceutical contract manufacturing organizations (CMO) in Europe. With Biomeva now a part of the AGC Group, AGC’s Life Science Business will be offering wider geographic coverage and a wider range of capacities, the Japanese firm noted.

Based in the Bio Cluster City of Heidelberg, Germany, Biomeva has almost 25 years of experience in providing contract development and manufacturing services using microbial expression technology to European and other International customers. Biomeva’s services include process development for highly efficient therapeutic protein expression, cGMP compliant fermentation, purification and bulk filling, as well as analytical testing and cell banking.